Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 4/23/26 | AbbVie (ABBV) | Trenibote for Wrinkles | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/22/26 | Anthos Therapeutics | abelacimab for Venous Thromboembolism (VTE) | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/21/26 | Praxis (PRAX) | PRAX-944 for Essential Tremor | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/13/26 | Eli Lilly and Company (LLY) | Jaypirca for Non-Hodgkin's Lymphoma (NHL) | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/13/26 | Eli Lilly and Company (LLY) | Jaypirca for Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 06/30/2022 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 06/30/2022 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 06/30/2022 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 10/22/2023 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 10/22/2023 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |